Form 4: Altimmune Director Buys 5,000 Shares

Altimmune Director Wayne Pisano acquired 5,000 shares of common stock at $4.082 per share, increasing his direct beneficial ownership to 13,498 shares.

Summary

• Wayne Pisano, a Director of Altimmune, Inc. (ALT), purchased 5,000 shares of the company's common stock.
• The transaction occurred on January 8, 2026, at a price of $4.082 per share.
• Following this acquisition, Mr. Pisano directly beneficially owns a total of 13,498 shares of Altimmune common stock.

Sentiment

Score: 7

Explanation: The sentiment is positive due to a director's purchase of company stock, which typically signals confidence in the company's future performance and valuation.

Positives

• A Director's purchase of company stock signals confidence in the company's future prospects and valuation.
• The acquisition increases the Director's personal stake, aligning his interests more closely with those of other shareholders.

Future Outlook

NA

Industry Context

Insider buying, particularly by a director, is often viewed by the market as a positive indicator, suggesting that those with intimate knowledge of the company believe its stock is undervalued or that positive developments are on the horizon. This transaction occurs within the broader context of the biotechnology industry, where company-specific news and insider sentiment can significantly influence investor perception.

Related Party Transactions

• The acquisition of 5,000 shares of common stock by Director Wayne Pisano is a related party transaction, as it involves an insider of the company.

Stakeholder Impact

• Shareholders may interpret the director's purchase as a positive signal, potentially increasing confidence in the company's stock.
• The transaction aligns the director's financial interests more closely with those of other shareholders.

Key Dates

Recommendation

While a director's purchase of company stock is a positive signal, indicating insider confidence, a single transaction of this size typically does not warrant an immediate 'buy' or 'strong buy' recommendation without a broader analysis of the company's financials, strategic outlook, and market conditions. It serves as a supportive data point for existing investors or those considering a position, suggesting a 'hold' for current investors and further due diligence for potential new investors.

Keywords

Altimmune, ALT, Insider Trading, Director Purchase, Stock Acquisition, Form 4, Beneficial Ownership